CN111601601A - 选择性p2x3调节剂 - Google Patents

选择性p2x3调节剂 Download PDF

Info

Publication number
CN111601601A
CN111601601A CN201880073147.XA CN201880073147A CN111601601A CN 111601601 A CN111601601 A CN 111601601A CN 201880073147 A CN201880073147 A CN 201880073147A CN 111601601 A CN111601601 A CN 111601601A
Authority
CN
China
Prior art keywords
selective
antagonist
patient
receptor antagonism
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880073147.XA
Other languages
English (en)
Chinese (zh)
Inventor
D.加索
A.马祖拉尼斯
R.贝里尼
K.帕伊扎
N.乔雷特
S.E.布朗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxosmithklay Intellectual Property No3 Co ltd
Original Assignee
Neomed Institute
Bellus Health Cough Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neomed Institute, Bellus Health Cough Inc filed Critical Neomed Institute
Publication of CN111601601A publication Critical patent/CN111601601A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Amplifiers (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Oscillators With Electromechanical Resonators (AREA)
CN201880073147.XA 2017-09-18 2018-09-14 选择性p2x3调节剂 Pending CN111601601A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762560077P 2017-09-18 2017-09-18
US62/560,077 2017-09-18
US15/936,316 US10111883B1 (en) 2017-09-18 2018-03-26 Selective P2X3 modulators
US15/936,316 2018-03-26
PCT/IB2018/001513 WO2019064079A2 (en) 2017-09-18 2018-09-14 SELECTIVE MODULATORS OF P2X3

Publications (1)

Publication Number Publication Date
CN111601601A true CN111601601A (zh) 2020-08-28

Family

ID=63894683

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880073147.XA Pending CN111601601A (zh) 2017-09-18 2018-09-14 选择性p2x3调节剂

Country Status (12)

Country Link
US (6) US10111883B1 (enExample)
EP (2) EP4331669A3 (enExample)
JP (1) JP7242681B2 (enExample)
KR (1) KR102713354B1 (enExample)
CN (1) CN111601601A (enExample)
AU (1) AU2018342751B2 (enExample)
CA (1) CA3076150C (enExample)
ES (1) ES2969868T3 (enExample)
IL (2) IL273348B2 (enExample)
MX (1) MX2020002968A (enExample)
SG (1) SG11202002460QA (enExample)
WO (1) WO2019064079A2 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112409331A (zh) * 2019-08-21 2021-02-26 上海翰森生物医药科技有限公司 杂环类衍生物抑制剂、其制备方法和应用
CN115043836A (zh) * 2021-08-20 2022-09-13 苏州璞正医药有限公司 一种咪唑并吡啶衍生物的p2x3受体选择性调节剂及其药物用途
WO2022258059A1 (zh) * 2021-06-10 2022-12-15 武汉朗来科技发展有限公司 一种药物组合物、制剂及其制备方法和应用

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019353424B2 (en) * 2018-10-05 2022-12-08 Shionogi & Co., Ltd. Medicine for treating chronic cough
AU2019358327B2 (en) * 2018-10-10 2025-04-24 Glaxosmithkline Intellectual Property (No. 3) Limited Treatment of pruritus with P2X3 antagonists
FI3880678T3 (fi) 2018-11-13 2025-08-01 Glaxosmithkline Intellectual Property N0 3 Ltd P2x3-muuntaja metyyli-(s)-2-((2-(2,6-difluori-4-(metyylikarbamoyyli)fenyyli)-7-metyyli-imidatso[1,2-a]pyridin-3-yyli)metyyli)morfoliini-4-karboksylaatin kidemuotoja
JP2022515879A (ja) * 2018-12-29 2022-02-22 武漢朗来科技発展有限公司 複素環式化合物、中間体、その製造方法及び応用 本願は、出願日が２０１８年１２月２９日の中国特許出願ｃｎ ２０１８１１６４２３１９、出願日が２０１９年０５月２４日の中国特許出願ｃｎ２０１９１０４４０２１４．３及び出願日が２０１９年１０月２４日の中国特許出願ｃｎ２０１９１１０１６１５８．７に基づいて優先権を主張する。また、上記中国特許出願の全文は本願に援用される。
WO2020174283A1 (en) * 2019-02-25 2020-09-03 Bellus Health Cough Inc. Treatment with p2x3 modulators
MX2022009762A (es) * 2020-02-14 2022-09-09 Bellus Health Cough Inc Moduladores del purinorreceptor 3 p2x (p2x3).
EP4142784A4 (en) 2020-04-27 2024-12-18 Twist Bioscience Corporation VARIANT NUCLEIC ACID BANKS FOR CORONAVIRUS
WO2021244634A1 (zh) * 2020-06-05 2021-12-09 武汉人福创新药物研发中心有限公司 咪唑并吡啶类化合物及其用途
CN114085220B (zh) * 2020-06-22 2023-06-16 上海海雁医药科技有限公司 取代的吗啉-4-羧酸酯衍生物、其组合物及医药上的用途
EP4169921A4 (en) * 2020-06-29 2024-06-19 Wuhan LL Science and Technology Development Co., Ltd. Crystalline form of heterocyclic compound, preparation method therefor and application thereof
US20240408131A1 (en) * 2020-07-06 2024-12-12 Sensory Cloud, Inc. Isotonic or hypertonic salt-based compositions
US20230218661A1 (en) * 2022-01-10 2023-07-13 Sensory Cloud, Inc. Isotonic or hypertonic salt-based compositions, treatments, devices, and articles for delivery of same to larynx
CN113912601B (zh) * 2020-07-10 2023-06-06 上海拓界生物医药科技有限公司 一类新的咪唑并[1,2-a]吡啶类衍生物、其制备方法及医药用途
CA3187092A1 (en) * 2020-08-13 2022-02-17 Wenming Li Benzimidazole derivatives, preparation method therefor and medical use thereof
CN116635389A (zh) * 2021-01-29 2023-08-22 上海海雁医药科技有限公司 吗啉衍生物及其药物组合物和用途
CN120917022A (zh) 2023-03-23 2025-11-07 葛兰素史密斯克莱知识产权(第3号)有限公司 氘代p2x3调节剂

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102741245A (zh) * 2009-11-18 2012-10-17 阿斯利康(瑞典)有限公司 苯并咪唑化合物及其用途
CN105246888A (zh) * 2013-01-31 2016-01-13 尼奥迈德研究所 咪唑并吡啶化合物及其用途
CN105682659A (zh) * 2013-08-23 2016-06-15 传入制药公司 用于治疗急性、亚急性或慢性咳嗽的二氨基嘧啶p2x3和p2x2/3受体调节剂
US20170326141A1 (en) * 2016-01-08 2017-11-16 Nerre Therapeutics Limited Method of treatment of chronic cough administering orvepitant in combination with other therapeutic agents

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101790370B1 (ko) * 2010-03-19 2017-10-25 유니버시티 오브 마이애미 췌장 베타 세포에서 인슐린 분비를 향상시키기 위한 ｐ２ｘ 퓨린성 수용체 효능제의 용도
RS63014B1 (sr) * 2014-12-09 2022-04-29 Bayer Ag 1,3-tiazol-2-il supstituisani benzamidi
LT3355889T (lt) 2015-09-29 2023-05-10 Afferent Pharmaceuticals Inc. Diaminopirimidino p2x3 ir p2x2/3 receptorių moduliatoriai, skirti panaudoti gydant kosulį
CN116854693A (zh) * 2016-09-30 2023-10-10 阿沙纳生物科学公司 P2x3和/或p2x2/3化合物及方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102741245A (zh) * 2009-11-18 2012-10-17 阿斯利康(瑞典)有限公司 苯并咪唑化合物及其用途
CN105246888A (zh) * 2013-01-31 2016-01-13 尼奥迈德研究所 咪唑并吡啶化合物及其用途
CN105682659A (zh) * 2013-08-23 2016-06-15 传入制药公司 用于治疗急性、亚急性或慢性咳嗽的二氨基嘧啶p2x3和p2x2/3受体调节剂
US20170326141A1 (en) * 2016-01-08 2017-11-16 Nerre Therapeutics Limited Method of treatment of chronic cough administering orvepitant in combination with other therapeutic agents

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112409331A (zh) * 2019-08-21 2021-02-26 上海翰森生物医药科技有限公司 杂环类衍生物抑制剂、其制备方法和应用
CN112409331B (zh) * 2019-08-21 2024-02-20 上海翰森生物医药科技有限公司 杂环类衍生物抑制剂、其制备方法和应用
WO2022258059A1 (zh) * 2021-06-10 2022-12-15 武汉朗来科技发展有限公司 一种药物组合物、制剂及其制备方法和应用
CN115043836A (zh) * 2021-08-20 2022-09-13 苏州璞正医药有限公司 一种咪唑并吡啶衍生物的p2x3受体选择性调节剂及其药物用途
WO2023020156A1 (zh) * 2021-08-20 2023-02-23 苏州璞正医药有限公司 一种咪唑并吡啶衍生物的p2x3受体选择性调节剂及其药物用途

Also Published As

Publication number Publication date
EP3684368A4 (en) 2021-05-26
CA3076150C (en) 2024-01-02
KR20200092938A (ko) 2020-08-04
US20200230148A1 (en) 2020-07-23
WO2019064079A2 (en) 2019-04-04
JP2020534355A (ja) 2020-11-26
EP4331669A2 (en) 2024-03-06
WO2019064079A3 (en) 2019-05-16
US20210069201A1 (en) 2021-03-11
US20210322432A1 (en) 2021-10-21
SG11202002460QA (en) 2020-04-29
KR102713354B1 (ko) 2024-10-02
US20220160724A1 (en) 2022-05-26
EP3684368B1 (en) 2024-01-03
JP7242681B2 (ja) 2023-03-20
AU2018342751B2 (en) 2023-06-15
AU2018342751A1 (en) 2020-04-23
IL303257A (en) 2023-07-01
US10111883B1 (en) 2018-10-30
US20230248736A1 (en) 2023-08-10
EP3684368B8 (en) 2024-02-14
MX2020002968A (es) 2020-08-17
EP4331669A3 (en) 2024-05-01
IL273348A (en) 2020-05-31
ES2969868T3 (es) 2024-05-23
CA3076150A1 (en) 2019-04-04
IL273348B1 (en) 2023-07-01
EP3684368A2 (en) 2020-07-29
IL273348B2 (en) 2023-11-01

Similar Documents

Publication Publication Date Title
CN111601601A (zh) 选择性p2x3调节剂
TW200813010A (en) Derivatives of 1-phenyl-2-pyridynyl alkylene alcohols as phosphodiesterase inhibitors
HUP0303624A2 (hu) NEP inhibitor hatású N-fenpropil-ciklopentil-csoporttal szubsztituált glutáramid származékok és ezeket tartalmazó gyógyászati készítmények és eljárás a vegyületek előállítására
US11555013B2 (en) Potent and selective inhibitors of monoamine transporters; method of making; and use thereof
BG107229A (bg) Циклопентил-заместени глутарамидни производни като инхибитори на неутрална ендопептидаза
JP2003128637A (ja) ジフルオロメチレン芳香族エーテル類
JP2005527621A (ja) アニリノ肝ｘ受容体調節因子
SK2012003A3 (en) Phenoxybenzylamine derivatives as selective re-uptake inhibitors
JPWO2014092061A1 (ja) ヒダントイン誘導体
HK40036201A (en) Selective p2x3 modulators
WO2002032842A2 (en) Compounds with high monoamine transporter affinity
JPH11507331A (ja) ４，４−（二置換）シクロヘキサン−１−オール類モノマーおよび関連化合物
WO1998021177A1 (en) Benzenesulfonamide derivatives and drugs containing the same
JP2008513380A (ja) ４級アンモニウム基を有するキヌクリジン化合物とその調製方法、およびアセチルコリン遮断剤としての用途
US9994548B2 (en) Phenyl-substituted nicotinic ligands, and methods of use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40036201

Country of ref document: HK

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20240117

Address after: Kaisan ohokkatsu

Applicant after: Bellus medical cough Co.

Address before: Kaisan ohokkatsu

Applicant before: Bellus medical cough Co.

Applicant before: NEOMED INSTITUTE

TA01 Transfer of patent application right

Effective date of registration: 20240617

Address after: Kaisan ohokkatsu

Applicant after: Belus Medical Co.

Country or region after: Canada

Address before: Kaisan ohokkatsu

Applicant before: Bellus medical cough Co.

Country or region before: Canada

TA01 Transfer of patent application right
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20240711

Address after: Kaisan ohokkatsu

Applicant after: 14245563 Canada Inc.

Country or region after: Canada

Address before: Kaisan ohokkatsu

Applicant before: Belus Medical Co.

Country or region before: Canada

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20240725

Address after: Kaisan ohokkatsu

Applicant after: ID BIOMEDICAL CORPORATION OF QUEBEC

Country or region after: Canada

Address before: Kaisan ohokkatsu

Applicant before: 14245563 Canada Inc.

Country or region before: Canada

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20240814

Address after: Steve Niki

Applicant after: GlaxoSmithKlay Intellectual Property (No.3) Co.,Ltd.

Country or region after: Britain

Address before: Kaisan ohokkatsu

Applicant before: ID BIOMEDICAL CORPORATION OF QUEBEC

Country or region before: Canada